Recursion Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Recursion Pharmaceuticals, Inc. | RXRX - NASDAQ |
$16.00-$18.00 | $18.00 | $30.00 | 24.2 million | 4/16/2021 |
| Goldman Sachs, JP Morgan, BofA Securities, SVB Leerink, Allen & Co. | ||||||
Co-Manager(s): KeyBanc Capital
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-03-22 Terms Added 2021-04-12 | ||||||
Recursion Pharmaceuticals, Inc. Quote & Chart - Click for current quote - RXRX
IPO Boutique aggregates information on public companies and private companies, such as "RXRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Recursion Pharmaceuticals, Inc. (adapted from Recursion Pharmaceuticals, Inc. prospectus):
They are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "RXRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.